Arvinas, Inc.
Every calculator, already run for ARVN
Open the full toolkit →You have the numbers on ARVN. Get the argument.
A written report on which of these readings actually decide the outcome for Arvinas, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
16 analysts covering ARVNAnalyst Price Target Disagreement for Arvinas, Inc.
Wall Street's bull case implies +177% from the current price; the bear case implies -21%. A 198% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ARVN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D m…
ARVN — frequently asked
Is ARVN a buy right now?
Wall Street's consensus rating on Arvinas, Inc. is Buy across 16 analysts, with a mean price target of $13.93 (+84% vs. the current $7.59). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ARVN overvalued?
ARVN trades at 29.2x trailing earnings. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ARVN's next earnings date?
Arvinas, Inc. is next scheduled to report earnings around Nov 4, 2026. A full ARVN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Arvinas, Inc.?
Analysts covering Arvinas, Inc. (ARVN) range from a bear-case target of $6.00 to a bull-case high of $21.00, with a mean consensus target of $13.93 across 14 analysts. The spread of $15.00 (198% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Arvinas, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Arvinas, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ARVN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Arvinas, Inc., in minutes. 3 free reports included with every account — no credit card required.